ArticleCancer research2011
The mef/elf4 transcription factor fine tunes the DNA damage response.
Article in Cancer research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 16 citations in OpenAlex.
- Review
- SCAMP3-Driven Regulation of ERK1/2 and Autophagy Phosphoproteomics Signatures in Triple-Negative Breast Cancer.International journal of molecular sciences · 2025Article
- "Deficiency in ELF4, X-Linked": a Monogenic Disease Entity Resembling Behçet's Syndrome and Inflammatory Bowel Disease.Journal of clinical immunology · 2024Article
- Loss of CMTM6 promotes DNA damage-induced cellular senescence and antitumor immunity.Oncoimmunology · 2022Article
- ELF4 is critical to zygotic gene activation and epigenetic reprogramming during early embryonic development in pigs.Frontiers in veterinary science · 2022Article
- Article
- HIPK2 is necessary for type I interferon-mediated antiviral immunity.Science signaling · 2019Article
- Characterization of Transcriptome Transition Associates Long Noncoding RNAs with Glioma Progression.Molecular therapy. Nucleic acids · 2018Article
- Common ELF1 deletion in prostate cancer bolsters oncogenic ETS function, inhibits senescence and promotes docetaxel resistance.Genes & cancer · 2018Article
- Roles and regulations of the ETS transcription factor ELF4/MEF.Journal of molecular cell biology · 2017Review
- Generation of a novel, multi-stage, progressive, and transplantable model of plasma cell neoplasms.Scientific reports · 2016Article
- Finding a fairy in the forest: ELF4, a novel and critical element of type I interferon responses.Cellular & molecular immunology · 2014Article
- Differential miRNA expression profiles in proliferating or differentiated keratinocytes in response to gamma irradiation.BMC genomics · 2013Article
- Inactivation of X-linked tumor suppressor genes in human cancer.Future oncology (London, England) · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
The ATM kinase plays a critical role in initiating the DNA damage response that is triggered by genotoxic stresses capable of inducing DNA double-strand breaks. Here, we show that ELF4/MEF, a member of the ETS family of transcription factors, contributes to the persistence of γH2AX DNA damage foci and promotes the DNA damage response leading to the induction of apoptosis. Conversely, the absence of ELF4 promotes the faster repair of damaged DNA and more rapid disappearance of γH2AX foci in response to γ-irradiation, leading to a radio-resistant phenotype despite normal ATM phosphorylation. Following γ-irradiation, ATM phosphorylates ELF4, leading to its degradation; a mutant form of ELF4 that cannot be phosphorylated by ATM persists following γ-irradiation, delaying the resolution of γH2AX foci and triggering an excessive DNA damage response. Thus, although ELF4 promotes the phosphorylation of H2AX by ATM, its activity must be dampened by ATM-dependent phosphorylation and degradation to avoid an excessive DNA damage response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.